News Center
Celebrating Clinical Trials Day
SOPHiA GENETICS is excited to celebrate Clinical Trials Day. This blog dives a little deeper into the history of clinical trials and how they continue to advance healthcare.
SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022
Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first...
Diversity in Genomic Analysis: An example of how SOPHiA GENETICS has built more accurate health data analysis for diverse populations
Every person is unique. We can clearly see this within the more than one million genomic profiles from 70 different countries analyzed by our technology.
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors
BOSTON, United States and LAUSANNE, Switzerland – May 5, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the...
April 2022 Newsletter
SOPHiA GENETICS analyzes one million genomic profilesHaving facilitated the analysis of one million...
Benefits of doing genomic data analysis in house
Third party sequencing services can enable increased access to NGS testing, but if institutions do not receive access to the raw data it can limit the insights they can gain. Doing the data analysis in house can allow you to harness the power of genomic data to reveal relevant variants.
A Milestone Worth Celebrating: One Million Genomic Profiles Analyzed
SOPHiA GENETICS has reached a major milestone on a global scale by analyzing one million genomic profiles.
SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform
BOSTON, United States and LAUSANNE, Switzerland – April 26, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position...
Expect more from your RNA analyses with the new SOPHiA DDM RNAtarget Technology
Q&A with the Clinical Application Product Manager, Mikhail Pertziger, PhD
Four key challenges in myeloid malignancy detection
Next generation sequencing has greatly enhanced our power for identifying mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
Evolution of precision medicine
The field of precision medicine continues to evolve but remains steadfast in its goal to provide the right treatment to the right patients at the right time. This blog examines the evolution of precision medicine and how we can achieve its promise.
Food for thought from ACMG 2022: Unleashing the potential of exome sequencing
Read our summary of top-rated research in the field of exome sequencing at the American College
of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2022.
Rare Disease Day 2022
Test your rare disease knowledge in our quiz for Rare Disease Day 2022!
